Nothing Special   »   [go: up one dir, main page]

PL2109623T3 - Leczenie nowotworu przeciwciałami przeciw il-1 - Google Patents

Leczenie nowotworu przeciwciałami przeciw il-1

Info

Publication number
PL2109623T3
PL2109623T3 PL07734628T PL07734628T PL2109623T3 PL 2109623 T3 PL2109623 T3 PL 2109623T3 PL 07734628 T PL07734628 T PL 07734628T PL 07734628 T PL07734628 T PL 07734628T PL 2109623 T3 PL2109623 T3 PL 2109623T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
antibodies
immunization
antibody
Prior art date
Application number
PL07734628T
Other languages
English (en)
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of PL2109623T3 publication Critical patent/PL2109623T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07734628T 2006-05-22 2007-05-22 Leczenie nowotworu przeciwciałami przeciw il-1 PL2109623T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80216606P 2006-05-22 2006-05-22
EP07734628A EP2109623B1 (en) 2006-05-22 2007-05-22 Treatment of cancer with anti-il-1 antibodies
PCT/IB2007/001320 WO2007135546A2 (en) 2006-05-22 2007-05-22 TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES

Publications (1)

Publication Number Publication Date
PL2109623T3 true PL2109623T3 (pl) 2012-03-30

Family

ID=38670649

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07734628T PL2109623T3 (pl) 2006-05-22 2007-05-22 Leczenie nowotworu przeciwciałami przeciw il-1

Country Status (15)

Country Link
US (3) US20100040574A1 (pl)
EP (1) EP2109623B1 (pl)
JP (3) JP2009537628A (pl)
CN (3) CN107158376A (pl)
AT (1) ATE528319T1 (pl)
AU (1) AU2007252990B2 (pl)
CA (1) CA2652870C (pl)
CY (1) CY1112288T1 (pl)
DK (1) DK2109623T3 (pl)
ES (1) ES2374845T3 (pl)
HK (1) HK1243943A1 (pl)
PL (1) PL2109623T3 (pl)
PT (1) PT2109623E (pl)
SI (1) SI2109623T1 (pl)
WO (1) WO2007135546A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015128A1 (en) 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
KR101567117B1 (ko) * 2008-05-30 2015-11-06 엑스바이오테크, 인크. 인터류킨-1 알파 항체 및 그의 사용 방법
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
CN104804089A (zh) 2010-05-14 2015-07-29 Abbvie公司 Il-1结合蛋白
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR20130108305A (ko) * 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
AU2015271978B2 (en) * 2010-08-23 2017-10-26 Xbiotech Inc. Treatment for neoplastic diseases
AU2015201228B2 (en) * 2010-08-23 2016-02-11 Xbiotech Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) * 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
WO2018150265A1 (en) 2017-02-16 2018-08-23 Xbiotech, Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095676A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPH06339394A (ja) * 1986-11-13 1994-12-13 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−１αに対するモノクローナル抗体
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
JPH02157231A (ja) * 1988-12-07 1990-06-18 Bio Kagaku Kenkyusho:Kk 細胞増殖抑制剤
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1994008624A2 (en) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
NZ605429A (en) * 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) * 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
WO2007015128A1 (en) * 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007132338A2 (en) * 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
NZ597251A (en) * 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
KR101567117B1 (ko) * 2008-05-30 2015-11-06 엑스바이오테크, 인크. 인터류킨-1 알파 항체 및 그의 사용 방법
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
CN102580086A (zh) 2012-07-18
CN101472948A (zh) 2009-07-01
JP2013126990A (ja) 2013-06-27
AU2007252990A1 (en) 2007-11-29
CA2652870C (en) 2014-12-02
JP6359492B2 (ja) 2018-07-18
US20190169287A1 (en) 2019-06-06
US20160159899A1 (en) 2016-06-09
SI2109623T1 (sl) 2012-05-31
US20100040574A1 (en) 2010-02-18
CA2652870A1 (en) 2007-11-29
ATE528319T1 (de) 2011-10-15
HK1243943A1 (zh) 2018-07-27
WO2007135546A3 (en) 2008-02-07
CN107158376A (zh) 2017-09-15
CY1112288T1 (el) 2015-12-09
JP5992843B2 (ja) 2016-09-14
EP2109623B1 (en) 2011-10-12
AU2007252990B2 (en) 2011-10-27
EP2109623A2 (en) 2009-10-21
PT2109623E (pt) 2012-01-12
ES2374845T3 (es) 2012-02-22
DK2109623T3 (da) 2012-01-30
WO2007135546A2 (en) 2007-11-29
JP2015166401A (ja) 2015-09-24
JP2009537628A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
MY150756A (en) Tumor theraphy with an anti-vegf antibody
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue